Alnylam Pharmaceuticals, Inc. which can be found using ticker (ALNY) now have 22 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $395.00 and $144.00 with the average share target price sitting at $228.95. (at the time of writing). Given that the stocks previous close was at $173.06 this would indicate that there is a potential upside of 32.3%. Also worth taking note is the 50 day moving average now sits at $181.48 while the 200 day moving average is $185.58. The market cap for the company is 21.42B. The stock price for the company is currently is currently $170.70 USD
The potential market cap would be $28,339,810,973 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of $13.86 and a -6.01% return on assets.
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes five marketed products and over ten clinical programs, including several in late-stage development, across four strategic therapeutic areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. Its RNAi-based medicines include ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1.
